# New analogues of fatty acids for the treatment of obesity, hypertension and fatty infiltration of the liver

**C07C327/06**- to hydrogen atoms or to carbon atoms of an acyclic saturated carbon skeleton

The invention relates to medicine and applies to new analogues of fatty acids of General formula (1), pharmaceutical compositions for and methods of treating or preventing obesity, hypertension, fatty infiltration of the liver, multiple metabolic syndrome nutritional compositions and method of improving the quality of such products as meat, milk and eggs. 9 C. and 35 C.p. f-crystals, 8 ill., 10 table.Description text in facsimile form (see graphic part).

Claims

1. Pharmaceutical composition for treatment and/or prevention of obesity, containing an effective amount of an analog of fatty acids of General formula (I)where n is an integer from 1 to 12;m is an integer from 0 to 23;i is an odd number, and specifies the position relative COOR;X_{i}independently from each other selected from the group consisting of O, S, SO, SO

_{2}, Se and CH

_{2};R represents hydrogen or C

_{1}-C

_{4}alkyl,provided that at least one of X

_{i}does not represent a CH

_{2},or its salt is the first song on p. 1, where X

_{i=3}selected from the group consisting of O, S, SO, SO

_{2}and Se, and where X

_{i=5-25}represents CH

_{2}.4. The pharmaceutical composition according to p. 3, where X

_{i=3}represents sulphur.5. The pharmaceutical composition according to p. 3, where X

_{i=3}represents selenium.6. Pharmaceutical composition for treating and/or preventing hypertension, containing an effective amount of an analog of fatty acids of General formula (I)where n is an integer from 1 to 12;m is an integer from 0 to 23;i is an odd number, and specifies the position relative COOR;X

_{i}independently from each other selected from the group consisting of O, S, SO, SO

_{2}, Se and CH

_{2};R represents hydrogen or C

_{1}-C

_{4}alkyl,provided that at least one of X

_{i}does not represent a CH

_{2},or its salts or prodrugs.7. The pharmaceutical composition according to p. 6, where m is equal to or greater than 13.8. The pharmaceutical composition according to p. 6, where X

_{i=3}selected from the group consisting of O, S, SO, SO

_{2}and Se, and where X

_{i=5-25}represents CH

_{2}.9. The pharmaceutical composition according to p. 8, where X

_{i=3}PR. Pharmaceutical composition for treatment and/or prevention of fatty infiltration of the liver, containing an effective amount of an analog of fatty acids of General formula (I)where n is an integer from 1 to 12;m is an integer from 0 to 23;i is an odd number, and specifies the position relative COOR;X

_{i}independently from each other selected from the group consisting of O, S, SO, SO

_{2}, Se and CH

_{2};R represents hydrogen or C

_{1}-C

_{4}alkyl,provided that at least one of X

_{i}does not represent a CH

_{2},or its salts or prodrugs.12. The pharmaceutical composition according to p. 11, where m is equal to or greater than 13.13. The pharmaceutical composition according to p. 11, where X

_{i=3}selected from the group consisting of O, S, SO, SO

_{2}and Se, and where X

_{i=5-25}represents CH

_{2}.14. The pharmaceutical composition according to p. 13, where X

_{i=3}represents sulphur.15. The pharmaceutical composition according to p. 13, where X

_{i=3}represents selenium.16. Pharmaceutical composition for treatment and/or prevention of multiple metabolic syndrome containing an effective amount of analou 1 to 12;m is an integer from 0 to 23;i is an odd number, and specifies the position relative COOR;X

_{i}independently from each other selected from the group consisting of O, S, SO, SO

_{2}, Se and CH

_{2};R represents hydrogen or C

_{1}-C

_{4}alkyl,provided that at least one of X

_{i}does not represent a CH

_{2},or its salts or prodrugs where multiple metabolic syndrome is marked with the term "metabolic syndrome", which, in particular, is characterized by hyperinsulinemia, insulin resistance, obesity, glucose intolerance, diabetes mellitus type 2, dyslipidemia and/or hypertension.17. The pharmaceutical composition according to p. 16, where m is equal to or greater than 13.18. The pharmaceutical composition according to p. 16, where X

_{i=3}selected from the group consisting of O, S, SO, SO

_{2}and Se, and where X

_{i=5-25}represents CH

_{2}.19. The pharmaceutical composition according to p. 18, where X

_{i=3}represents sulphur.20. The pharmaceutical composition according to p. 18, where X

_{i=3}represents selenium.21. Similar fatty acids of General formula Iwhere n is an integer from 1 to 12;m is positive COOR;X

_{i}independently from each other selected from the group consisting of O, S, SO, SO

_{2}, Se and CH

_{2};R represents hydrogen or C

_{1}-C

_{4}alkyl,provided that at least one of X

_{i}does not represent a CH

_{2},provided that if the formula contains only 1 X

_{i}that does not represent a-CH

_{2}- X

_{i=3}does not represent O, S, SO, SO

_{2}Seor its salt or the prodrug.22. A method of treating or preventing the condition of obesity or overweight, at which stage the introduction of the needy in this animal an effective amount of analogues of fatty acids of General formula (I)where n is an integer from 1 to 12;m is an integer from 0 to 23;i is an odd number, and specifies the position relative COOR;X

_{i}independently from each other selected from the group consisting of O, S, SO, SO

_{2}, Se and CH

_{2};R represents hydrogen or C

_{1}-C

_{4}alkyl,provided that at least one of X

_{i}does not represent a CH

_{2},or their salts or prodrugs.23. The method according to p. 22, where the specified vividly istvanne animal such as chickens, cows, sheep, goats or pigs.25. The method according to p. 22, where the specified animal is a domestic animal such as a dog or cat.26. The method according to p. 22, where the specified animal is a fish or crustaceans, such as salmon, cod, Tilapia, clams, oysters, lobsters or crabs.27. The method according to p. 22, where m is equal to or greater than 13.28. The method according to one of paragraphs.22-27, where X

_{i=3}selected from the group consisting of O, S, SO, SO

_{2}and Se, and where X

_{i=5-25}represents CH

_{2}.29. The method according to p. 28, where X

_{i=3}represents sulphur.30. The method according to p. 28, where X

_{i=3}represents selenium.31. The method according to any of paragraphs.22-30, in which analogues of fatty acids administered in such a way that their therapeutically effective concentration essentially continuously supported in the blood of the animal during the period of their introduction.32. The method according to any of paragraphs.22-31, where the composition of such analogs of fatty acids made in the form of a standard dosage forms.33. Nutritional composition for reducing or preventing the increase in total body mass or total mass of body fat in animals, including humans, contain an effective amount analogues of fatty acids is dstanley an integer from 0 to 23;i is an odd number, and specifies the position relative COOR;X

_{i}independently from each other selected from the group consisting of O, S, SO, SO

_{2}, Se and CH

_{2};R represents hydrogen or C

_{1}-C

_{4}alkyl,provided that at least one of X

_{i}does not represent a CH

_{2},provided that if the formula contains only 1 X

_{i}that does not represent a-CH

_{2}- X

_{i=3}does not represent O, S, SO, SO

_{2}Seor their salts or prodrugs.34. The way to reduce weight or reduce body fat mass in in need thereof of a human or animal in which it is administered an effective amount of a composition containing analogues of fatty acids of General formula (I)where n is an integer from 1 to 12;m is an integer from 0 to 23;i is an odd number, and specifies the position relative COOR;X

_{i}independently from each other selected from the group consisting of O, S, SO, SO

_{2}, Se and CH

_{2};R represents hydrogen or C

_{1}-C

_{4}alkyl,provided that at least one of X

_{i}does not represent a CH

_{2},or the WMD from p. 34 or 35, where the animal is adapted to a small energy.37. The method according to one of paragraphs.34-36, where m is equal to or greater than 13.38. The method according to p. 36, where X

_{i=3}selected from the group consisting of O, S, SO, SO

_{2}and Se, and where X

_{i=5-25}represents CH

_{2}.39. The method according to p. 38, where X

_{i=3}represents sulphur.40. The method according to p. 38, where X

_{i=3}represents selenium.41. The method according to p. 35 or 36, where the specified animal is a human.42. How to change the distribution and fat content in animals to improve the quality of the meat or products such as milk and eggs in the diet of the animals add nutritional product containing analogues of fatty acids of the formula (I)where n is an integer from 1 to 12;m is an integer from 0 to 23;i is an odd number, and specifies the position relative COOR;X

_{i}independently from each other selected from the group consisting of O, S, SO, SO

_{2}, Se and CH

_{2};R represents hydrogen or C

_{1}-C

_{4}alkyl,provided that at least one of X

_{i}does not represent a CH

_{2},or the salt or the prodrug.43. The method according to p. 42, where the decree is I.44. The method according to p. 42, where the specified animal is a fish or crustaceans, such as salmon, cod, Tilapia, clams, oysters, lobsters or crabs.

**Same patents:**

The invention relates to new compounds of the formula (I)

< / BR>

where AG represents a radical selected from formulas (a) and (b) below:

< / BR>

R

< / BR>

where AG represents a radical selected from formulas (a) and (b) below:

< / BR>

R

_{1}represents a halogen atom, -CH_{3}CH_{2}OR SIG_{7}, -OR SIG_{7}, СОR_{8}, R_{2}and R_{3}taken together form a 5 - or 6-membered ring, R_{4}and R_{5}represent H, a halogen atom, a C_{1}-C_{10}-alkyl, R_{7}represents H, R_{8}represents H orX represents the radical-Y-C-, r' and r" is H, C_{1}-C_{10}alkyl, phenyl, Y represents S(O)_{n}or SE, n = 0, 1, or 2, and salts of compounds of formula (I)1-methoxy-1-(2-chlorpheniramine)alkanes, exhibiting anti-inflammatory and antimicrobial activity // 2030399

The invention relates to selenoorganicheskikh compounds, namely 1-methoxy-1-(2-chlorpheniramine)alkanal formula I

CH

CH

_{3}-O-H-SEwhere R is methyl or isopropyl, exhibiting anti-inflammatory and antimicrobial activityThe invention relates to new biologically active compounds, specifically to hydrochloridum of aminosilanes aromatic series formula I

= CH-Se-Ar where R is methyl; R

Ar - p-or-were, p-chlorophenyl or- naphthyl, showing a phosphate-protecting action

= CH-Se-Ar where R is methyl; R

_{1}is methyl or ethyl;Ar - p-or-were, p-chlorophenyl or- naphthyl, showing a phosphate-protecting action

The method of producing divorcioyacuerdo // 2021261

The invention relates to a method of producing foramerica diverticulae acid, which is used as a reagent in the synthesis of organofluorine

The invention relates to a compound having the formula

< / BR>

or its pharmaceutically acceptable salts, where R

< / BR>

or its pharmaceutically acceptable salts, where R

^{1}represents tetrazolyl; R^{4}, R^{5}and R^{2}each independently selected from hydrogen, alkyl, alkoxy, hydroxy, halogen, and so on, or aryl, possibly substituted CON(R^{9})_{2}, NHCOR^{9}, SO_{2}N(R^{9})_{2}, CO_{2}R^{9}where R^{9}represents hydrogen, alkyl, cycloalkyl and tSolid dosage form based on carvedilola // 2214243

The invention relates to medicine, specifically to a solid dosage form carvedilola made in the form of a solid dosage form containing carvedilol and pharmaceutically acceptable excipients, which are used starch, saccharide, stearic acid and/or its salt, having the stability during storage

The invention relates to medicine, more precisely to the pharmacy, and can be used for the preparation of solid pharmaceutical compositions, the active compound which is enalapril maleate

The diuretic and antihypertensive agent // 2207128

The invention relates to medicine, in particular to pharmaceutical drugs used in diseases of the cardiovascular system

The invention relates to medicine, namely cardiology, and for the treatment of hypertension in combination with coronary heart disease

The invention relates to the field of medicine and is suitable for the treatment of hypertension and congestive heart failure

The invention relates to medicine, specifically to pharmaceutical compositions comprising as active ingredient indapamide, and may find application in the treatment of hypertension and to prevent the delay of sodium and water in the body in chronic heart failure

The invention relates to medicine and can be used for the integrated treatment of edematic-fibrosclerotic panniculopathy (cellulite)

The invention relates to medicine and can be used in dentistry to prevent patients suffering from arterial hypertension and elevated risk factor in orthodontic treatment

The invention relates to the field of veterinary medicine

Antihypoxic tool // 2213571